EGFR and non-small cell lung carcinoma: Consistent with this assertion, EGFR has a known GOF mutation (EGFR H773L) in this position that eliminates hydrogen-bonding and has been shown to be sensitive to EGFR kinase inhibitors in non-small cell lung cancer (76).